A Case-Based Approach to Early Intervention in Schizophrenia
Optimizing Service Provision

12 SEPTEMBER 2020 | 15:50 - 17:20
SESSION: ISS.02

VIRTUAL EVENT
MODERATOR

John Kane, MD
Professor and Chairman
Department of Psychiatry
The Donald and Barbra Zucker School of Medicine at Hofstra/Northwell
Chair
Department of Psychiatry
The Zucker Hillside Hospital
Glen Oaks, New York, United States

DISCLOSURES
John Kane, MD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Allergan; Alkermes; Eli Lilly; Genentech; Intracellular Therapies; Janssen; Johnson & Johnson; Merck; Neurocrine; Otsuka; Pierre Fabre; Revive; Roche; Sunovion; Takeda; Teva

Received grants for clinical research from: Janssen; Lundbeck; Otsuka

Owns stock, stock options, or bonds from: Vanguard Research Group; LB Pharmaceuticals

PANELISTS

Charlotte Emborg Mafi, MD
Chief Medical Officer
OPUS - Clinic for Young People with Schizophrenia
Aarhus University Hospital
Aarhus, Denmark

DISCLOSURES
Charlotte Emborg Mafi, MD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Lundbeck; Otsuka; Recordati

Served as a speaker or a member of a speakers bureau for: Lundbeck; Otsuka; Recordati

Robin Emsley, MBChB, DCH
Professor in Psychiatry
Sarah Turoff Endowed Chair in Schizophrenia Research
Faculty of Medicine and Health Sciences
Stellenbosch University
Cape Town, South Africa

DISCLOSURES
Robin Emsley, MBChB, DCH, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Janssen; Lundbeck; Servier

Served as a speaker or a member of a speakers bureau for: Janssen; Lundbeck; Servier

Tara Niendam, PhD
Associate Professor
Department of Psychiatry
Executive Director
Early Psychosis Programs
University of California, Davis
Sacramento, California, United States

DISCLOSURES
Tara Niendam, PhD, has disclosed the following relevant financial relationships:

Other: Cofounder and shareholder of Safari Health Inc.
PROGRAM INFORMATION

OVERVIEW
The goal of this activity is to improve clinicians’ recognition of early phase schizophrenia, implementing long-acting therapies early on, and optimal service provision for patients with schizophrenia.

TARGET AUDIENCE
This activity is intended for an international audience of non-US psychiatrists, and neurologists.

LEARNING OBJECTIVES
Upon completion of this activity, participants will:

- Have increased knowledge regarding the
  • Emerging and latest clinical insights into the benefits of early treatment of schizophrenia with long-acting injectable (LAI) antipsychotics

- Have greater competence related to
  • Effectively diagnosing early schizophrenia
  • Effectively managing early schizophrenia with LAIs
  • Recognizing the benefits of a multidisciplinary team and best-practice infrastructure to manage early schizophrenia more optimally

ACCREDITATION STATEMENT
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.50 continuing professional development credits (CPD).

AGENDA
Welcome and Introduction
John Kane, MD

The First Psychotic Episode: What Does It Mean for the Long-Term?
Tara Niendam, PhD

Challenges in Managing Schizophrenia: How Might We Do Better?
Robin Emsley, MBChB, DCH

Recent Insights Into LAIs for Early Schizophrenia: Key Trial Update
John Kane, MD

Completing the Jigsaw Puzzle: Putting It All Into Practice
Charlotte Emborg Mafi, MD

Discussion

Live Q&A

Closing Remarks
John Kane, MD